2842-37-7

Basic information

• Product Name: 2-(Phenethylamino)ethanol
• Synonyms: 2-(phenethylamino)ethanol;2-[(2-Phenylethyl)amino]ethan-1-ol;2-[(2-phenylethyl)amino]Ethanol
• CAS NO: 2842-37-7
• Molecular Formula: C₁₀H₁₅NO
• Molecular Weight: 165.23
• Mol File: 2842-37-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 293.09°C (rough estimate)
• Flash Point: 128.4 °C
• Appearance: /
• Density: 1.0203 (rough estimate)
• Vapor Pressure: 0.000443mmHg at 25°C
• Refractive Index: 1.5200 (estimate)
• CAS DataBase Reference: 2-(Phenethylamino)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Phenethylamino)ethanol(2842-37-7)
• EPA Substance Registry System: 2-(Phenethylamino)ethanol(2842-37-7)

Safety Data

• Hazardous Substances Data: 2842-37-7(Hazardous Substances Data)

Usage

General Description

2-(Phenethylamino)ethanol is a chemical compound that consists of a phenethylamine group linked to an ethanol group. It is commonly used as a component in some drugs and pharmaceuticals due to its potential effects as a central nervous system depressant and vasodilator. The compound can also act as a precursor in the synthesis of various chemicals and is used in research and development of new pharmaceuticals. In addition, it has been studied for its potential use in the treatment of certain medical conditions. Overall, 2-(Phenethylamino)ethanol plays a significant role in the pharmaceutical and chemical industries due to its potential therapeutic effects and versatility in synthesis.

InChI:InChI=1/C10H15NO/c12-9-8-11-7-6-10-4-2-1-3-5-10/h1-5,11-12H,6-9H2

Upstream product

• 622-24-2 2-phenylethyl chloride 
• 141-43-5 ethanolamine 
• 585-71-7 (1-bromoethyl)benzne 
• 415932-36-4 2-[benzyl(phenethyl)amino]ethanol 
• 122-78-1 phenylacetaldehyde 
• 64-04-0 phenethylamine 
• 4846-84-8 hydroxyacetyl-2-phenylethylamine 
• 103-63-9 1-phenyl-2-bromoethane 

Downstream Products

• 82909-52-2 3,4-bis(benzyloxy)-N-phenethyl-N-(2-hydroxyethyl)bicyclo<4.2.0>octa-1,3,5-triene-7-carboxamide 
• 3484-94-4 3-phenethyl-thiazolidine-2-thione 
• 948588-58-7 C₁₇H₁₈N₂OS 
• 949902-88-9 (2-hydroxyethyl)phenethylcarbamic acid t-butyl ester 
• 1420476-84-1 7-bromo-2-phenethyl-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione 
• 145549-11-7 tert-butyl (R)-3-phenylpyrrolidine-1-carboxylate 
• 182921-00-2 (2-oxoethyl)phenethylcarbamic acid t-butyl ester 
• 300547-19-7 1-[(1S)-1-Benzyl-2-(dimethylamino) ethyl]-3-(2-hydroxyethyl)-3-phenethyl urea 
• 872007-48-2 methanesulfonic acid 2-(methanesulfonyl-phenethyl-amino)-ethyl ester 
• 82909-53-3 3,4-bis(benzyloxy)-N-(2-oxoethyl)-N-phenethylbicyclo<4.2.0>octa-1,3,5-triene-7-carboxamide 
• 948588-63-4 C₂₇H₂₈N₂O₃S 
• 1055034-84-8 (4S,5R,6R)-5-Acetylamino-4-tert-butoxycarbonylamino-6-[(2-hydroxy-ethyl)-phenethyl-carbamoyl]-5,6-dihydro-4H-pyran-2-carboxylic acid benzhydryl ester 

Relevant articles and documents

Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist

The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed to a growing opioid epidemic in the United States. Gastrointestinal dysfunction is an additional serious consequence of opioid use, and this can be treated with a localized drug distribution of a non-CNS penetrant, peripherally restricted opioid receptor antagonist. Herein, we describe the application of Theravance's multivalent approach to drug discovery coupled with a physicochemical property design strategy by which the N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenyl carboxamide series of μ-opioid receptor antagonists was optimized to afford the orally absorbed, non-CNS penetrant, Phase 3 ready clinical compound axelopran (TD-1211) 19i as a potential treatment for opioid-induced constipation.

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure - based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.